CNO Financial Group, Inc. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
CNO Financial Group, Inc. is a holding company for a group of insurance companies focusing on health insurance, annuities, and individual life insurance for middle-income pre-retiree and retired Americans. The company operates through three primary product lines (Annuity, Health, Life) and two sales divisions (Consumer and Worksite). This report covers the fiscal year ended December 31, 2024.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenues | $4.45 billion | $4.15 billion |
| Net Income | $404.0 million | $276.5 million |
| Net Operating Income (Non-GAAP) | $429.3 million | $356.1 million |
| Total Assets | $37.9 billion | $35.0 billion |
| Shareholders' Equity | $2.5 billion | $2.2 billion |
| Premium Collections | $4.38 billion | $4.10 billion |
| Insurance Product Margin | $1.04 billion | $959.0 million |
| Debt to Total Capitalization | 30.5% | 34.0% |
Material Changes vs. Prior Period
- Profitability Growth: Net income increased 46% to $404.0 million, driven by higher insurance product margins and improved investment income not allocated to product lines.
- Segment Performance:
- Annuity Margin: Increased to $274.2 million (from $235.0 million), aided by a $36.2 million favorable actuarial adjustment related to higher mortality assumptions.
- Health Margin: Rose to $516.8 million (from $494.3 million), with Long-Term Care margin improving significantly to $133.1 million due to favorable claim experience.
- Life Margin: Increased to $249.0 million (from $229.7 million), supported by lower advertising expenses and block growth.
- Investment Portfolio: Total investments grew to $27.9 billion. The portfolio includes $22.8 billion in fixed maturities. Net investment income rose to $1.75 billion, reflecting higher portfolio yields (4.80% average yield on allocated investments).
- Capital Actions: The company issued $700 million of 6.450% Senior Notes due 2034 in May 2024. It also repurchased 8.9 million shares of common stock for $281.6 million.
Guidance, Outlook, and Risks
- 2025 Outlook: Management expects operating earnings per diluted share in the range of $3.70 to $3.90. The expense ratio is expected to range from 19.0% to 19.4%. Excess cash flow to the holding company is projected between $200 million and $250 million.
- Technology Initiative: A three-year technology modernization project begins in Q2 2025, expected to cost approximately $170 million total ($60 million in 2025). These costs will be excluded from operating earnings.
- Key Risks:
- Interest Rate Risk: Sensitivity to changes in interest rates affecting investment spreads and policyholder surrenders. Approximately $3.4 billion of insurance liabilities could be surrendered without penalty.
- Regulatory Risk: Dependence on regulatory approval for rate increases on health products (Long-Term Care, Medicare Supplement) and dividend payments from subsidiaries.
- Investment Risk: Exposure to credit losses and unrealized losses in the fixed maturity portfolio, particularly in structured securities (31% of fixed maturities).
- Reinsurance Risk: Reliance on third-party reinsurers; failure of a reinsurer could negatively impact earnings.
Investor Verification Checklist
- Actuarial Assumptions: Verify the sustainability of the favorable $27.3 million actuarial adjustment in 2024, specifically regarding mortality assumptions in annuities and morbidity in health products.
- Dividend Capacity: Confirm the ability of U.S. insurance subsidiaries to pay dividends to the holding company, noting that several subsidiaries currently have negative earned surplus requiring regulatory approval for distributions.
- Investment Portfolio Quality: Review the composition of the $2.5 billion in gross unrealized losses within fixed maturities and the adequacy of the $37.1 million allowance for credit losses.
- Debt Covenants: Monitor compliance with the Revolving Credit Agreement covenants, specifically the debt-to-total capitalization ratio (currently 30.5% vs. 35.0% limit).
- Rate Increase Approvals: Track the status of pending rate increase filings for Long-Term Care and Medicare Supplement products, as denial could materially impact future margins.